Recent studies have identified tumor-derived microvesicles called exosomes as vehicles for long-distance communication, due to their complex content of proteins and microRNAs. In head and neck squamous cell carcinoma, as in many other cancers, exosome secretion is associated with advanced patient stage. In most cases, those vesicles are classified as exosomes, 50-100 nm vesicles that have been shown to mediate progression, metastasis, survival, drug resistance, immune modulation, and many other aggressive cancer phenotypes. The mechanisms by which exosomes are generated are poorly understood, although exosomes are known to derive from a late endocytic compartment. Our recent preliminary data suggest that invadopodia are sites of exosome secretion and that, conversely, canonical invadopodia regulators affect exosome secretion. Based on these and other findings, we hypothesize that exocytic late endosomal/lysosomal pathways that govern invadopodia activity and exosome secretion may be one and the same. Furthermore, these pathways are likely to be unregulated in the 30-40% of HNSCC tumors that carry amplification of the 11q13.3 amplicon, since we have shown that the 11q13-amplified cytoskeletal protein cortactin is a key regulator of invadopodia activity, exosome secretion, and tumor aggressiveness. In this project, we will test whether invadopodia represent docking sites for exosomes and identify key intracellular regulatory points for exosome secretion by HNSCC cells. We will also test the hypothesis that 11q13-amplification is an independent predictor of exosome secretion in HNSCC patients. Finally, we will determine whether inhibition of exosome secretion represents a viable therapeutic strategy in HNSCC.
This project will study the mechanism and impact of exosome secretion in head and neck squamous cell carcinoma progression. The project is relevant to public health because it will lead to a greater understanding of mechanisms that lead to head and neck cancer aggressiveness and test whether anti-exosome targeting is a promising therapeutic option.
| Sato, Shinya; Weaver, Alissa M (2018) Extracellular vesicles: important collaborators in cancer progression. Essays Biochem 62:149-163 |
| Erdogan, Begum; Ao, Mingfang; White, Lauren M et al. (2017) Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin. J Cell Biol 216:3799-3816 |
| Maas, Sybren L N; Breakefield, Xandra O; Weaver, Alissa M (2017) Extracellular Vesicles: Unique Intercellular Delivery Vehicles. Trends Cell Biol 27:172-188 |
| Sung, Bong Hwan; Weaver, Alissa M (2017) Exosome secretion promotes chemotaxis of cancer cells. Cell Adh Migr 11:187-195 |
| Parekh, Aron; Weaver, Alissa M (2016) Regulation of invadopodia by mechanical signaling. Exp Cell Res 343:89-95 |
| Sinha, Seema; Hoshino, Daisuke; Hong, Nan Hyung et al. (2016) Cortactin promotes exosome secretion by controlling branched actin dynamics. J Cell Biol 214:197-213 |
| Siqueira, Adriane S; Pinto, Monique P; Cruz, Mário C et al. (2016) Laminin-111 peptide C16 regulates invadopodia activity of malignant cells through ?1 integrin, Src and ERK 1/2. Oncotarget 7:47904-47917 |
| Sung, Bong Hwan; Ketova, Tatiana; Hoshino, Daisuke et al. (2015) Directional cell movement through tissues is controlled by exosome secretion. Nat Commun 6:7164 |
| Cleghorn, Whitney M; Branch, Kevin M; Kook, Seunghyi et al. (2015) Arrestins regulate cell spreading and motility via focal adhesion dynamics. Mol Biol Cell 26:622-35 |
| Koshikawa, Naohiko; Hoshino, Daisuke; Taniguchi, Hiroaki et al. (2015) Proteolysis of EphA2 Converts It from a Tumor Suppressor to an Oncoprotein. Cancer Res 75:3327-39 |
Showing the most recent 10 out of 15 publications
